Waters NuGenesis is not the chromatography system

Assign each scientific record to the system that creates it

A chromatography data system ordinarily controls the instrument sequence, acquisition parameters, original signals, processing method, integrations, calculations, results, reprocessing history, and instrument-specific audit evidence. An SDMS can collect and preserve files and metadata from that environment, while an LMS or electronic laboratory notebook can coordinate samples, procedures, observations, review, and reporting. Connection among those records does not make the systems interchangeable.

The architecture record should name the original data object, method and version, instrument, acquisition system, analyst, sample, result, transformation, reviewer, archive copy, retention rule, and authoritative system at every lifecycle stage. A central repository can improve discovery and preservation without becoming the application that generated or scientifically interpreted the chromatography record.

Test the CDS-to-SDMS handoff as an evidence chain

A buyer demonstration should start with one representative injection and follow the original data, metadata, sequence, method, result, audit history, report, and related sample record from the chromatography system into NuGenesis. The team should see which objects are copied, referenced, transformed, indexed, rendered, or left behind and whether the archived package can be reconstructed with the required context.

The test should include a failed capture, a renamed file, a reprocessed result, a superseded method, a late transfer, a duplicate, changed permissions, legal hold, restore, and export. Buyers should identify which system detects each exception, who resolves it, what evidence is retained, and whether the source and repository remain synchronized without silently overwriting history.

Keep documented controls separate from validation conclusions

Waters documents workflow, repository, electronic-signature, version-control, audit-trail, security, and regulated-environment positioning. Those are provider claims about available product functions. They do not prove that a particular laboratory configured the functions for an intended use, tested representative risks, controlled procedures and access, trained users, or retained adequate lifecycle evidence.

A defensible review links each predicate requirement and intended use to configured behavior, risk assessment, specification, test, deviation, approval, change record, and operating control. Labels such as compliance-ready, structural integrity, or centralized repository cannot establish Part 11 compliance, GxP validation, data integrity, method suitability, accreditation, or scientific validity for a customer.

Preserve the unknowns the product page cannot answer

The official page establishes current public positioning and named capabilities, not a customer's licensed modules, versions, deployment, instrument estate, interface depth, capture rules, file formats, latency, failure recovery, migration, archive readability, or support model. It also does not provide an independent comparison with a chromatography data system or a configured workflow test.

Lab Systems Index reviewed the official record on August 10, 2026. Buyers should verify current documentation, release notes, contracts, architecture, validation support, export behavior, and a representative end-to-end evidence chain before assigning record authority.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

Lab Systems Index will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.